Navigation Links
Veteran International Health Care Executive Appointed CEO of BeneChill(R)
Date:6/4/2010

SAN DIEGO and STOCKHOLM, June 4 /PRNewswire/ -- Amgen executive Alan Raffensperger has been appointed the new Chief Executive Officer of BeneChill, a privately held medical device company launching its first product, a novel cooling device for use by emergency response teams in the field, later this year in Europe.  With more than 25 years of experience in the pharmaceutical, biotechnology, medical device and diagnostic industries, Mr. Raffensperger joins BeneChill from his post as Executive Director and Franchise Head of Nephrology for Amgen, a global biopharmaceutical company.  He joined Amgen in 2005 as General Manager of the Nordic and Baltic Region, overseeing operations in eight countries from his Sweden base.

(Photo:  http://photos.prnewswire.com/prnh/20100604/LA15970)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100604/LA15970)

"As we prepare to launch our lead RhinoChill™ product in Europe, it was critical that we recruit a seasoned, well-rounded CEO with big pharma experience and the sensitivity to a smaller company," said Denise Barbut, M.D., Executive Chair and founder of BeneChill. "Alan's stellar track record and experience in product development, sales and marketing will enable us to achieve our business goals."

Prior to Amgen, Mr. Raffensperger was with Hoffman La Roche for ten years with his most recent position as Head of Pharmaceutical Marketing and Sales for Roche in Sweden. Previously, he was the CEO for Swedemed, a privately-held developer of an advanced ultrasonic surgery system. He began his career with Pharmacia, first in sales in the U.S. and then product management in Sweden.

Earlier in his career, Mr. Raffensperger was a paramedic for National Hospital in Arlington, VA and notes that his experience in cardiovascular and trauma emergency care provides a solid foundation for understanding the need for BeneChill's cooling devices in the field.  He received his Bachelor of Science degree in Emergency Health Sciences Management from the University of Maryland and was an MBA candidate at George Washington University.  He is a nationally registered EMT-paramedic.

BeneChill® is a privately held medical device company that develops novel, rapid cooling systems to improve survival after cardiac arrest.  RhinoChill™ can be administered quickly and directly to the brain by a proprietary portable system that uses a nasal catheter to deliver a rapid evaporative coolant and will be marketed in Europe later this year. With corporate headquarters in San Diego, CA, BeneChill will be opening offices in Switzerland.  


'/>"/>
SOURCE BeneChill
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Legion Anticipates Institute of Medicine Report on Gulf War Veterans
2. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
3. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
4. Secretary Reinforces VAs Commitment to Research Safety and Veteran Focus
5. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
6. Congresswoman Supporting Spinal Cord Research Intended to Benefit U.S. Veterans
7. NovaRx Appoints Industry Veteran as President and COO
8. For Iraq Veterans, Headaches Continue After Traumatic Brain Injury
9. Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO
10. Biotechnology Salutes Americas Veterans; Innovations Continue to Offer Improved Treatment and Care of Combat Troops
11. FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017  A new tight-tolerance microextrusion ... other highly-engineered materials, is being launched by Natvar, ... been developed in recent years to service a ... surgical applications. More expensive materials such as glass ... tubing due to their ability to consistently hold ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... and NEW YORK ... As the leading distributor of market intelligence, ... European Med Tech Reimbursement Consulting AB that ... Tech Reimbursement Consulting AB,s proprietary market analyses through the ... professionals around the world easy access to complete product ...
Breaking Medicine Technology:
(Date:5/23/2017)... , ... May 23, 2017 , ... ... North Carolina have remained steady since 2009, according to a Workers Compensation Research ... The study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and a 2017 Best in KLAS category winner, has named Daniel P. Bullington ... extend and enhance its technology platform and product offerings,” says Justin Neece, president. ...
(Date:5/23/2017)... ... , ... London, May 23, 2017: Walter Schindler, the Founder and Managing Partner ... Speaker and Contributor to a weeklong series of classes, meetings, field trips and special ... Walter Schindler and SAIL Capital have received an increasing number of ...
(Date:5/23/2017)... ... May 23, 2017 , ... By all indications, and due to months of ... call for diligence, asking homeowners to scout for any open water sources that can ... the annoying buzz of mosquitos is the buzz associated with potential infections stemming from ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech For Solutions has announced ... laboratory, to provide hands-on training utilizing cutting-edge equipment at its recently-opened OvaTools Andrology ... MedTech Group Purchasing vendor , will provide specialized equipment to ensure OvaTools participants ...
Breaking Medicine News(10 mins):